Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Dateline City:
KENILWORTH, N.J.
Third Approval for KEYTRUDA in First-Line NSCLC in China in Less Than One Year
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China in combination with carboplatin and paclitaxel for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).
Language:
English
Contact:
Media Contacts:
Pamela Eisele
(267) 305-3558
Justine Moore
(347) 281-3754
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Michael DeCarbo
(908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE